论文部分内容阅读
我们采用免疫组化S－P法，对17例石蜡包埋睑板腺癌及癌旁组织标本的P53突变蛋白表达进行了检测。结果：17例癌组织有12例表达阳性，阳性率71％。其中分化型7例，6例呈阳性（86％）表达。在一组原发灶及淋巴结转移癌配对标本中，同一病人之两个部位P(53)突变蛋白表达差异无明显意义。癌旁（睑缘）组织17例中5例上皮有异常增生，且同时伴有P(53)突变蛋白呈强阳性表达。以上结果提示：抑癌基因P53的突变在睑板腺癌的发生中是一个比较常见的基因改变，且在分化型癌的发生中表现明显；P(53)基因异常发生在肿瘤转移之前且在淋巴道转移中可能起重要作用；P(53)突变蛋白在癌旁上皮异型增生组织中的过度表达具有十分重要的意义。
We used immunohistochemical S-P method, 17 cases of paraffin-embedded meibomian gland cancer and adjacent tissue specimens of P53 mutant protein expression was detected. Results: In 17 cases of carcinoma, 12 cases were positive, the positive rate was 71%. Among them, 7 were differentiated and 6 were positive (86%). There was no significant difference in the expression of P (53) mutein between the two groups in the same patient in a matched group of primary tumor and lymph node metastasis. In the 17 cases of paracancer (eyelid) tissues, 5 cases of epithelial dysplasia accompanied by strong positive expression of P (53) mutein. The above results suggest that the mutation of the tumor suppressor gene P53 is a common gene change in the occurrence of meibomian gland carcinoma and is obvious in the occurrence of differentiated carcinomas. The abnormality of P (53) gene occurs before tumor metastasis and in Lymph node metastasis may play an important role; P (53) mutein in epithelial dysplasia tissue over-expression is of great significance.